Willkie Farr & Gallagher advises PAI Partners on Zydus Lifesciences’ €256.8 million acquisition of Amplitude Surgical’s ...

Equities researchers at DA Davidson raised their FY2026 earnings per share (EPS) estimates for Amplitude in a report issued on Tuesday, March 11th. DA Davidson analyst C. Wright now forecasts that the ...

SAN FRANCISCO, March 07, 2025--(BUSINESS WIRE)--Amplitude (Nasdaq: AMPL), the leading digital analytics platform, will host its previously announced investor day on Monday, March 10, 2025 beginning at ...

Amplitude (NASDAQ:AMPL – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They currently have a $16.

Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopaedics and ...

Brokerage firms remain divided on Zydus Lifesciences as the company announced to acquire France-based Amplitude Surgical for ...

Amplitude's enterprise sales strategy is driving significant ARR growth. See why I reiterate my buy rating on AMPL stock.

Zydus Lifesciences on Tuesday said it has entered into exclusive negotiations to acquire a majority stake in France-based ...

India still relies largely on imported devices and implants, when it comes to MedTech. This offers us a great opportunity to ...

Medical Technology includes medical devices and related scientific infrastructure that directly contribute to the development ...

Regulatory News: Zydus Lifesciences Limited2 ("Zydus"), a global innovation-driven lifesciences company has entered into exclusive negotiations to purchase3 from PAI Partners and Amplitude Surgical’s ...

Zydus will file a mandatory cash tender offer for the remaining shares of Amplitude at the same purchase price of €6.25 per ...